Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of tetrandrine tablets on cytokines, immune function, blood gas and respiratory function in patients with stage II pneumoconiosis

Yan Wang¹, Hongliang Li², Li Song³, Xiuwu Liu⁴

¹Department of Environment and Occupational Health, Linyi Center for Disease Control and Prevention, Linyi 276000, Shandong Province, China; ²Department of Orthopedics, Linyi People's Hospital, Linyi 276000, Shandong Province, China; ³Linyi Center for Disease Control and Prevention, People's Hospital of Linyi City, Linyi 276000, Shandong Province, China; ⁴Department of Respiratory Medicine, People's Hospital of Linyi City, Linyi 276000, Shandong Province, China.

For correspondence:- Xiuwu Liu Email: jingxiemei89673@163.com

Accepted: 18 May 2024 Published: 30 June 2024

Citation: Wang Y, Li H, Song L, Liu X. Effect of tetrandrine tablets on cytokines, immune function, blood gas and respiratory function in patients with stage II pneumoconiosis. Trop J Pharm Res 2024; 23(6):993-1000 doi: 10.4314/tjpr.v23i6.10

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the impact of tetrandrine tablets on cytokines, immune function, blood gas and respiratory function in patients with stage II pneumoconiosis.

Methods: 136 subjects with stage II pneumoconiosis diagnosed and treated in People's Hospital of Linyi City, Linyi City, China were divided into control and study cohorts, each with 68 individuals. Patients in control cohort received conventional symptomatic treatment, while study cohort additionally received tetrandrine tablets orally 3 times per day, for 4 weeks. Lung function, serum indicators and blood gas indicators were determined before and after treatment.

Results: After treatment, the levels of forced expiratory volume in one second (FEV1) and FEV1/FVC in both groups were significantly increased in both cohorts, with significantly higher values in study cohort. In both cohorts, there were higher post-treatment numbers of CD4⁺ and CD8⁺ cells and CD4⁺/CD8⁺ ratio than before treatment, but with significantly higher values in study cohort (p < 0.05). After treatment, there were significantly raised levels of peripheral capillary oxygen saturation (SpO₂), minute ventilation (VE) and tidal volume (VT) in the two cohorts, with higher values in the study group cohort (p < 0.05). Moreover, treatment resulted in a significant reduction in partial pressure of end-tidal carbon dioxide (PETCO₂), with significantly lower levels in study cohort (p < 0.05). After treatment, concentrations of interleukin-1 beta (IL-1β), matrix metalloproteinase-7 (MMP-7), and tumor necrosis factor beta-1 (TNF-β1) in study cohort were significantly reduced, relative to pre-treatment.

Conclusion: Tetrandrine tablets are efficacious in stage II pneumoconiosis patients. The drug is beneficial in improving immune function, reducing levels of inflammatory mediators, and improving lung function and blood gas indicators in patients. Future studies incorporating additional parameters and a larger number of patients will be required to provide a more comprehensive understanding of the efficacy and safety of this treatment protocol.

Keywords: Tetrandrine tablets, Stage II pneumoconiosis, Cytokines, Immune function, Blood gas indicators